Inozyme Pharma, Inc. (INZY)
After hours:
- GlobeNewswire
Inozyme Pharma to Participate in the Piper Sandler 36th Annual Healthcare Conference
BOSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced that Matt Winton, Ph.D., Senior Vice President and Chief Operating Officer of Inozyme, will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024 from 2:30-2:55pm ET.
- Zacks
Here's Why Inozyme Pharma (INZY) is Poised for a Turnaround After Losing -29.98% in 4 Weeks
Inozyme Pharma (INZY) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
